Routine delivery footage already captured during the procedure.
Quantifies delivery characteristics including precision, smoothness, instability, tremor, and repositioning activity.
AI-supported findings aligned with sponsor-defined procedural, imaging, safety, and clinical endpoints.
DexteraAI's initial focus is retinal gene and cell therapy programs requiring subretinal delivery. These trials involve high-value biologic products, technically demanding surgical administration, and narrow regulatory and adoption pathways because established intravitreal therapies already exist for major retinal diseases.
The current commercial use case is retrospective analysis of existing surgical video, focused on the critical subretinal delivery maneuver.
Retrospective analysis is available now; later-stage applications depend on validation and program needs.
Evaluate whether delivery characteristics are associated with sponsor-defined procedural, safety, imaging, or clinical endpoints.
Track validated delivery characteristics across surgeons, sites, cases, and time.
Use validated procedural biomarkers to help interpret variation in efficacy, safety, imaging, or durability.
Use validated findings to support onboarding, training, workflow refinement, and post-market monitoring.
If you are developing a therapy that requires subretinal delivery and want to understand procedural variability in existing trial video, we would like to hear about it.